S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Longeveron (LGVN) Competitors

$1.92
-0.09 (-4.48%)
(As of 04/19/2024 ET)

LGVN vs. HEPA, MTEM, ADIL, VIRI, CYCN, AKTX, BFRI, GRTX, TFFP, and AEZS

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Hepion Pharmaceuticals (HEPA), Molecular Templates (MTEM), Adial Pharmaceuticals (ADIL), Virios Therapeutics (VIRI), Cyclerion Therapeutics (CYCN), Akari Therapeutics (AKTX), Biofrontera (BFRI), Galera Therapeutics (GRTX), TFF Pharmaceuticals (TFFP), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.

Longeveron vs.

Hepion Pharmaceuticals (NASDAQ:HEPA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Longeveron. MarketBeat recorded 10 mentions for Hepion Pharmaceuticals and 9 mentions for Longeveron. Longeveron's average media sentiment score of 0.31 beat Hepion Pharmaceuticals' score of 0.29 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hepion Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longeveron
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 2.0% of Hepion Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Longeveron has higher revenue and earnings than Hepion Pharmaceuticals. Longeveron is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$42.20M-$12.32-0.16
Longeveron$710K6.79-$21.41M-$10.20-0.19

Hepion Pharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Longeveron has a consensus price target of $60.00, suggesting a potential upside of 3,025.00%. Given Hepion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Hepion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hepion Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Longeveron
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Hepion Pharmaceuticals received 15 more outperform votes than Longeveron when rated by MarketBeat users. However, 85.71% of users gave Longeveron an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Hepion PharmaceuticalsOutperform Votes
21
67.74%
Underperform Votes
10
32.26%
LongeveronOutperform Votes
6
85.71%
Underperform Votes
1
14.29%

Hepion Pharmaceuticals has a net margin of 0.00% compared to Hepion Pharmaceuticals' net margin of -3,020.17%. Longeveron's return on equity of -145.58% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -145.58% -104.36%
Longeveron -3,020.17%-209.14%-136.82%

Summary

Hepion Pharmaceuticals beats Longeveron on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

MetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.83M$6.39B$4.89B$7.32B
Dividend YieldN/A3.10%2.93%3.96%
P/E Ratio-0.196.36146.0314.69
Price / Sales6.79306.062,467.5282.00
Price / CashN/A28.9747.3134.38
Price / Book0.725.324.564.15
Net Income-$21.41M$139.72M$104.37M$214.00M
7 Day Performance13.61%-6.71%-4.52%-3.51%
1 Month Performance-50.77%-9.67%-6.80%-6.05%
1 Year Performance-93.29%-6.54%6.60%3.98%

Longeveron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEPA
Hepion Pharmaceuticals
0.1233 of 5 stars
$2.04
-6.4%
N/A-86.4%$8.85MN/A0.0025News Coverage
MTEM
Molecular Templates
1.1303 of 5 stars
$1.66
-6.7%
N/A-78.0%$8.91M$57.31M-1.07111Gap Down
ADIL
Adial Pharmaceuticals
0 of 5 stars
$2.24
-14.2%
N/A-70.4%$9.07MN/A-0.3916
VIRI
Virios Therapeutics
0 of 5 stars
$0.45
-4.3%
N/A-36.4%$8.62MN/A-1.604Positive News
Gap Up
CYCN
Cyclerion Therapeutics
0 of 5 stars
$3.15
-5.1%
N/A-45.3%$8.54M$1.62M-0.571Short Interest ↓
News Coverage
Positive News
AKTX
Akari Therapeutics
0 of 5 stars
$1.16
-3.3%
N/A-72.2%$9.19MN/A0.0015Analyst Report
BFRI
Biofrontera
2.3841 of 5 stars
$1.81
+10.4%
$18.00
+894.5%
-85.9%$9.21M$34.07M-0.1183Positive News
GRTX
Galera Therapeutics
0 of 5 stars
$0.17
+13.3%
N/A-93.4%$9.25MN/A-0.1231Positive News
TFFP
TFF Pharmaceuticals
1.8813 of 5 stars
$3.31
-6.0%
$72.00
+2,075.2%
-81.5%$8.34M$730,000.00-0.2615
AEZS
Aeterna Zentaris
1.738 of 5 stars
$1.96
flat
$15.00
+665.3%
-35.2%$9.53M$4.50M-0.5711

Related Companies and Tools

This page (NASDAQ:LGVN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners